Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application for its drug Darzalex Faspro in ...
The application is for the treatment, called darzalex faspro, to be used in combination with an existing multiple myeloma treatment -- called bortezomib, lenalidomide and dexamethasone -- for adult ...
Investor's Business Daily on MSN5h
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple MyelomaLegend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...
Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...
2d
Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
3d
Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback